Review the steps for preparing and administering TEFLARO.
600 mg IV (over 5 to 60 minutes) every 12 hours for CABP 5-7 days and for ABSSSI 5-14 days*
*For patients with CrCl >50 mL/min.
Creatinine clearance (CrCl) estimated using the Cockcroft-Gault formula.
End-stage renal disease is defined as CrCl <15 mL/min.
TEFLARO is hemodialyzable; thus TEFLARO should be administered after hemodialysis on hemodialysis days.
5 to 60 minute IV infusion for TEFLARO1 | |
![]() |
In the treatment of ABSSSI and CABP, a 5 to 60 minute infusion allows...
Questions to consider
|
5 to 60 minute IV infusion for TEFLARO1 | |
![]() |
|
In the treatment of ABSSSI and CABP, a 5 to 60 minute infusion allows...
Questions to consider
|
Unreconstituted TEFLARO vials should be stored at room temperature, 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Please see individual product label for storage instructions and product expiration date.
Weight-based dosing is required for pediatric patients. See Dosing for Pediatric Patients.
No clinical drug-drug interaction studies have been conducted with TEFLARO.
There is minimal potential for drug-drug interactions between TEFLARO and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow.
CPK=creatine phosphokinase.
SSRIs=selective serotonin reuptake inhibitors.
These hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
These hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
Please also see full Prescribing Information.
Please also see full Prescribing Information.